Search - tctmd.com

Displaying 641 - 660 of 778

Sort: Relevancy | Date

News Features

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Michael O'Riordan

October 29, 2018

News Daily News

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Michael O'Riordan

October 25, 2018

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Daily News

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

Michael O'Riordan

October 19, 2018

News Daily News

Weekend Discharge Not Linked to More Readmissions After Cardiac Surgery

Michael O'Riordan

October 12, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Daily News

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Michael O'Riordan

September 20, 2018

News Daily News

Cath Lab Preactivated Less Than Half the Time in STEMI Cases: ACTION Registry

Michael O'Riordan

September 18, 2018

News Daily News

Benefits of Dairy, Particularly Milk and Yogurt, Get Boost in New PURE Analysis

Michael O'Riordan

September 13, 2018

News Daily News

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

Michael O'Riordan

September 12, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Daily News

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

Michael O'Riordan

August 14, 2018

News Daily News

‘We Have to Go to Them’: New Global Initiative for Treating Rheumatic Heart Disease

Michael O'Riordan

August 06, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

News Daily News

Discharge Against Medical Advice After PCI Rare but Deadly

Michael O'Riordan

July 17, 2018

News Daily News

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Michael O'Riordan

July 16, 2018

News Daily News

USPSTF: Insufficient Evidence to Support CAC Score, hsCRP, or ABI for Risk Assessment

Michael O'Riordan

July 12, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

Advertisement

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60%

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

FDA Approves HeartMate 3 as Destination Therapy in Advanced HF

Weekend Discharge Not Linked to More Readmissions After Cardiac Surgery

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Cath Lab Preactivated Less Than Half the Time in STEMI Cases: ACTION Registry

Benefits of Dairy, Particularly Milk and Yogurt, Get Boost in New PURE Analysis

Early Discharge Safe in Patients Undergoing TAVR, Meta-analysis Shows

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

‘We Have to Go to Them’: New Global Initiative for Treating Rheumatic Heart Disease

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Discharge Against Medical Advice After PCI Rare but Deadly

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

USPSTF: Insufficient Evidence to Support CAC Score, hsCRP, or ABI for Risk Assessment

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content